Clinical Trial Update: A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk [Phase 4]

View source ↗

Summary

This document reports an ongoing Phase 4 clinical trial of AK112, a PD-1/VEGF bispecific antibody, for resectable hepatocellular carcinoma with high recurrence …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK112

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: HCC | Phase 4 | Status: RECRUITING